PMID- 36882993
OWN - NLM
STAT- MEDLINE
DCOM- 20231005
LR  - 20231005
IS  - 1945-8932 (Electronic)
IS  - 1945-8932 (Linking)
VI  - 37
IP  - 6
DP  - 2023 Nov
TI  - Co-treatment with Fexofenadine and Budesonide Increases FoxP3 Gene Expression in 
      Patients with Allergic Rhinitis.
PG  - 623-629
LID - 10.1177/19458924231160596 [doi]
AB  - BACKGROUND: T helper type 2 (Th2), Th17, and regulatory T cells (Tregs) play 
      essential roles in the pathogenesis and control of allergic rhinitis (AR). 
      Fexofenadine and budesonide are first-line treatments for AR. This study aimed to 
      investigate the effect of co-treatment with fexofenadine and budesonide on the 
      expression of Th2, Th17, and Treg-specific transcription factors (GATA-binding 
      protein 3 [GATA-3], RAR-related orphan receptor gamma [RORgammat], and forkhead box 
      P3 [FoxP3], respectively) in AR patients. METHODS: In this study, 29 AR patients 
      were co-treated with fexofenadine and budesonide for 1 month. Blood was collected 
      from AR patients before and after 1 month of treatment. The gene expression 
      levels of GATA-3, RORgammat, and FoxP3 transcription factors in blood samples were 
      measured. In addition, serum immunoglobulin E (IgE) levels and eosinophil 
      percentages in blood samples were determined. FINDINGS: The expression level of 
      FoxP3 increased significantly after treatment compared with that before treatment 
      (P < .001). In contrast, GATA-3 and RORgammat expression levels did not show any 
      noticeable changes. In addition, the percentage of peripheral blood eosinophils 
      significantly decreased (P < .01). Serum IgE levels decreased compared with those 
      before treatment, but the difference was not statistically significant. 
      Furthermore, the clinical symptoms of the patients improved compared with those 
      before treatment. CONCLUSION: Our results showed that combined treatment with 
      fexofenadine and budesonide increased the expression level of the FoxP3 gene, 
      decreased the percentage of peripheral blood eosinophils, and improved the 
      clinical symptoms of AR patients. This regimen appears to improve disease 
      symptoms, at least in part by increasing the Treg population and decreasing the 
      eosinophil population.
FAU - Bagherinia, Elham
AU  - Bagherinia E
AD  - Student Research Committee, School of Medicine, Kermanshah University of Medical 
      Sciences, Kermanshah, Iran. RINGGOLD: 48463
FAU - Falahi, Sara
AU  - Falahi S
AD  - Student Research Committee, School of Medicine, Kermanshah University of Medical 
      Sciences, Kermanshah, Iran. RINGGOLD: 48463
FAU - Mortazavi, Seyed Hamidreza
AU  - Mortazavi SH
AD  - Department of Pediatrics, School of Medicine, Kermanshah University of Medical 
      Sciences, Kermanshah, Iran. RINGGOLD: 48464
FAU - Salari, Farhad
AU  - Salari F
AD  - Department of Immunology, School of Medicine, Kermanshah University of Medical 
      Sciences, Kermanshah, Iran. RINGGOLD: 48464
FAU - Rezaiemanesh, Alireza
AU  - Rezaiemanesh A
AD  - Department of Immunology, School of Medicine, Kermanshah University of Medical 
      Sciences, Kermanshah, Iran. RINGGOLD: 48464
FAU - Karaji, Ali Gorgin
AU  - Karaji AG
AUID- ORCID: 0000-0003-4537-5722
AD  - Department of Immunology, School of Medicine, Kermanshah University of Medical 
      Sciences, Kermanshah, Iran. RINGGOLD: 48464
LA  - eng
PT  - Journal Article
DEP - 20230307
PL  - United States
TA  - Am J Rhinol Allergy
JT  - American journal of rhinology & allergy
JID - 101490775
RN  - 51333-22-3 (Budesonide)
RN  - E6582LOH6V (fexofenadine)
RN  - 0 (Forkhead Transcription Factors)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 0 (Nuclear Receptor Subfamily 1, Group F, Member 3)
RN  - 0 (Transcription Factors)
SB  - IM
MH  - Humans
MH  - *Budesonide/therapeutic use/pharmacology
MH  - Forkhead Transcription Factors/genetics/metabolism
MH  - Gene Expression
MH  - Immunoglobulin E
MH  - Nuclear Receptor Subfamily 1, Group F, Member 3/genetics/metabolism
MH  - *Rhinitis, Allergic/drug therapy/genetics/metabolism
MH  - T-Lymphocytes, Regulatory/metabolism
MH  - Th17 Cells
MH  - Transcription Factors/genetics/metabolism
OTO - NOTNLM
OT  - budesonide, fexofenadine, FoxP3, allergic rhinitis, eosinophils, Treg
COIS- Declaration of Conflicting InterestsThe author(s) declared no potential conflicts 
      of interest with respect to the research, authorship, and/or publication of this 
      article.
EDAT- 2023/03/09 06:00
MHDA- 2023/10/04 06:44
CRDT- 2023/03/08 01:33
PHST- 2023/10/04 06:44 [medline]
PHST- 2023/03/09 06:00 [pubmed]
PHST- 2023/03/08 01:33 [entrez]
AID - 10.1177/19458924231160596 [doi]
PST - ppublish
SO  - Am J Rhinol Allergy. 2023 Nov;37(6):623-629. doi: 10.1177/19458924231160596. Epub 
      2023 Mar 7.